X

The ASCO Post

The ASCO Post

More extensive surgery does not improve survival over less aggressive surgery in younger women with breast cancer, according to data presented at the 2022 American Society of...

The ASCO Post
05/25/2022

Use of multiple immune pathway inhibitors appears to be superior to checkpoint inhibitor therapy alone as neoadjuvant therapy for resectable non–small cell lung cancer (NSCLC)...

The ASCO Post
05/25/2022

A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and...

The ASCO Post
05/24/2022

The US Food and Drug Administration approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).

The ASCO Post
05/23/2022

New findings from researchers at Memorial Sloan Kettering Cancer Center published by Shukla et al in Nature Communications reported the results of using a comprehensive sequencing approach...

The ASCO Post
05/19/2022

Medicaid expansion under the Affordable Care Act (ACA) was associated with an increase in 2-year overall survival rates among patients newly diagnosed with cancer...

The ASCO Post
05/19/2022

In a study reported in the Journal of Clinical Oncology, Bruinink et al constructed a transcriptomic classifier for primary plasma cell leukemia that identified high-risk PCL-like disease in...

The ASCO Post
05/19/2022

Kenzik et al found substantial rates of rehospitalization and emergency department visits after chimeric antigen receptor (CAR) T-cell therapy among commercially insured patients with cancer.

The ASCO Post
05/12/2022

 Heudel et al found that the addition of the mTOR inhibitor vistusertib to anastrozole improved outcomes in women with hormone receptor–positive recurrent or metastatic endometrial cancer.

The ASCO Post
05/17/2022

Patients with hormone receptor–positive, HER2-negative, early-stage breast cancer had similar Oncotype DX recurrence scores (RS) whether they had node-positive or node-negative disease.

The ASCO Post
05/12/2022
Subscribe to The ASCO Post

source list reference

RGB(78, 191, 50)
rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(80,199,199)
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(80,199,199)
rgb(252, 3, 223)
rgb (132, 101, 173)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
RGB(171, 29, 196)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (132, 101, 173)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
rgb (132, 101, 173)
rgb(181, 112, 164)
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
#cc529a
#c59445
rgb(245, 111, 66)
#c8cc0c
#bf6be3
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(11, 160, 224)
#e8085a
rgb(66, 135, 245)
#97d1a0
rgb(101, 11, 212)
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(125, 127, 130)
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
#2c990a
rbg(16, 162, 230)
rgb(110, 57, 65)
#d7da81
#f5ce42
rgb(80,199,199)
rgb(217, 7, 192)
#575662
rgb (247, 7, 79)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
rgb(214, 139, 202)
rgb (132, 101, 173)
rgb(10, 191, 137)
#c20fce
rgb(80,199,199)
#d95d39
#eb5834